Jacobson, Ira <br/><br/>
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.  [electronic resource] 

 -  World journal of gastroenterology  Mar 2016 
 - 3418-31 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2219-2840 
<br/><br/><label>Standard No.: </label>10.3748/wjg.v22.i12.3418  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antiviral Agents--adverse effects<br/>Carbamates<br/>Drug Resistance, Viral--genetics<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--diagnosis<br/>Humans<br/>Imidazoles--adverse effects<br/>Interferon-alpha--adverse effects<br/>Interferons<br/>Interleukins--genetics<br/>Male<br/>Middle Aged<br/>Oligopeptides--adverse effects<br/>Polyethylene Glycols--adverse effects<br/>Polymorphism, Genetic<br/>Pyrrolidines<br/>RNA, Viral--blood<br/>Recombinant Proteins--adverse effects<br/>Ribavirin--adverse effects<br/>Time Factors<br/>Treatment Outcome<br/>Valine--analogs & derivatives<br/>Viral Load<br/>Viral Nonstructural Proteins--antagonists & inhibitors<br/>Young Adult